Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOGNASDAQ:ATRANASDAQ:MOLNNASDAQ:RNAZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$9.14+5.2%$5.85$3.75▼$11.40$146.42M2.4897,353 shs192,142 shsATRAAtara Biotherapeutics$7.14+0.4%$6.65$5.01▼$18.71$42.56M0.3124,883 shs59,986 shsMOLNMolecular Partners$4.05+4.2%$3.94$3.36▼$12.70$163.68M1.1521,031 shs10,089 shsRNAZTransCode Therapeutics$6.97-8.5%$11.98$6.15▼$1,838.76$5.81M1.52100,387 shs63,917 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition+5.18%+5.66%+85.77%+45.54%+913,999,900.00%ATRAAtara Biotherapeutics+0.42%+4.39%+3.48%+0.42%-59.19%MOLNMolecular Partners+4.22%+5.57%0.00%-15.91%+6.68%RNAZTransCode Therapeutics-8.53%-14.58%-20.72%-96.92%-99.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACOGAlpha Cognition1.4809 of 5 stars3.50.00.00.02.30.80.0ATRAAtara Biotherapeutics4.0377 of 5 stars3.33.00.04.71.72.50.6MOLNMolecular Partners2.1741 of 5 stars3.82.00.00.03.30.00.6RNAZTransCode Therapeutics2.6378 of 5 stars3.52.00.00.04.40.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$20.00118.82% UpsideATRAAtara Biotherapeutics 2.57Moderate Buy$17.75148.60% UpsideMOLNMolecular Partners 3.50Strong Buy$12.00196.00% UpsideRNAZTransCode Therapeutics 3.00Buy$280.003,917.22% UpsideCurrent Analyst Ratings BreakdownLatest ATRA, ACOG, MOLN, and RNAZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025ACOGAlpha CognitionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/16/2025RNAZTransCode TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$560.00 ➝ $280.003/31/2025ACOGAlpha CognitionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/25/2025ACOGAlpha CognitionRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy3/18/2025ACOGAlpha CognitionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.003/13/2025RNAZTransCode TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$560.00 ➝ $560.003/11/2025ATRAAtara BiotherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/11/2025MOLNMolecular PartnersLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha Cognition$2.93M50.00N/AN/A($1.08) per share-8.46ATRAAtara Biotherapeutics$199.73M0.21N/AN/A($24.34) per share-0.29MOLNMolecular Partners$2.23M73.33N/AN/A$5.41 per share0.75RNAZTransCode TherapeuticsN/AN/AN/AN/A$86.32 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$13.77M-$1.20N/A∞N/AN/AN/A-344.17%8/11/2025 (Estimated)ATRAAtara Biotherapeutics-$276.13M-$3.72N/AN/AN/A-132.58%N/A-90.16%8/11/2025 (Estimated)MOLNMolecular Partners-$69.04M-$1.92N/AN/AN/A-1,043.01%-39.31%-35.46%N/ARNAZTransCode Therapeutics-$18.55MN/A0.00N/AN/AN/A-649.03%-281.34%N/ALatest ATRA, ACOG, MOLN, and RNAZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q4 2024RNAZTransCode Therapeutics-$2.00-$0.60+$1.40-$2.51$0.30 millionN/A5/15/2025Q1 2025ACOGAlpha Cognition-$0.58-$0.20+$0.38-$0.13$0.50 million$2.93 million5/15/2025Q1 2025ATRAAtara Biotherapeutics-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million5/15/2025Q1 2025MOLNMolecular Partners-$0.3855-$0.50-$0.1145-$0.50N/AN/A3/31/2025Q4 2024ACOGAlpha Cognition-$0.48-$0.51-$0.03-$0.51N/AN/A3/7/2025Q4 2024ATRAAtara Biotherapeutics-$3.82-$1.19+$2.63-$1.19$20.58 million$32.75 million3/6/2025H2 2024MOLNMolecular Partners-$0.45-$0.34+$0.11-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/ARNAZTransCode TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A1.501.50ATRAAtara BiotherapeuticsN/A0.590.50MOLNMolecular PartnersN/A14.3314.33RNAZTransCode TherapeuticsN/A1.581.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/AATRAAtara Biotherapeutics70.90%MOLNMolecular Partners26.55%RNAZTransCode TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%ATRAAtara Biotherapeutics3.70%MOLNMolecular Partners5.93%RNAZTransCode Therapeutics0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A16.02 million10.97 millionN/AATRAAtara Biotherapeutics3305.96 million5.55 millionOptionableMOLNMolecular Partners18040.38 million37.97 millionNot OptionableRNAZTransCode Therapeutics9833,000677,000Not OptionableATRA, ACOG, MOLN, and RNAZ HeadlinesRecent News About These CompaniesTransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities ReportedMay 8, 2025 | prnewswire.comTransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock SplitMay 6, 2025 | finanznachrichten.deTransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock SplitMay 5, 2025 | prnewswire.comTransCode Therapeutics approves reverse stock split to meet Nasdaq rulesMay 4, 2025 | investing.comTransCode reports progress in metastatic cancer trialMay 3, 2025 | uk.investing.comTransCode Therapeutics Announces 1-for-28 Reverse Stock SplitMay 2, 2025 | prnewswire.comIBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138May 2, 2025 | finance.yahoo.comTransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138May 2, 2025 | financial-news.co.ukTransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic CancerMay 1, 2025 | prnewswire.comTransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special MeetingApril 21, 2025 | prnewswire.comAll You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to BuyApril 18, 2025 | zacks.comTranscode Therapeutics price target lowered to $10 from $20 at H.C. WainwrightApril 17, 2025 | markets.businessinsider.comTranscode Therapeutics begins dosing in fourth cohort of Phase 1 cancer trialMarch 28, 2025 | markets.businessinsider.comTransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138March 28, 2025 | finanznachrichten.deTransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138March 27, 2025 | prnewswire.comTransCode Therapeutics, Inc. Announces Closing of Registered Direct OfferingMarch 25, 2025 | prnewswire.comTranscode to sell 10.25M shares at 98c per share in registered direct offeringMarch 25, 2025 | markets.businessinsider.comTransCode Therapeutics stock slides after announces to raise $10M securities offeringMarch 24, 2025 | msn.comTransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 23, 2025 | prnewswire.comTranscode Therapeutics’ fourth cohort in Phase 1/2 cancer trial approvedMarch 13, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?After Earnings Beats, These 3 Stocks Are on Analysts’ RadarsBy Leo Miller | May 20, 2025View After Earnings Beats, These 3 Stocks Are on Analysts’ RadarsATRA, ACOG, MOLN, and RNAZ Company DescriptionsAlpha Cognition NASDAQ:ACOG$9.14 +0.45 (+5.18%) As of 05/23/2025 04:00 PM EasternAlpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Atara Biotherapeutics NASDAQ:ATRA$7.14 +0.03 (+0.42%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$7.32 +0.19 (+2.59%) As of 05/23/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Molecular Partners NASDAQ:MOLN$4.05 +0.16 (+4.22%) Closing price 05/23/2025 03:56 PM EasternExtended Trading$4.06 +0.00 (+0.02%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.TransCode Therapeutics NASDAQ:RNAZ$6.97 -0.65 (-8.53%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$7.30 +0.33 (+4.66%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
